About HighTide Therapeutics
HighTide Therapeutics is a company based in Rockville (United States) founded in 2011. HighTide Therapeutics has raised $107 million across 2 funding rounds from investors including CITIC, TCM Health Care and Yuexiu Capital. The company has 70 employees. HighTide Therapeutics operates in a competitive market with competitors including NGM Biopharmaceuticals, Ironwood Pharma, Nimbus Therapeutics, Adocia and Altimmune, among others.
- Headquarter Rockville, United States
- Employees 70
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website hightidetx.com
- Social LinkedIn
- Legal Name Hightide Therapeutics Inc
- Net Profit-$34.13 M (USD)35.82as on Dec 31, 2025
- EBITDA-$30.28 M (USD)50.47as on Dec 31, 2025
- Total Equity Funding$107M (USD)
in 2 rounds
- Latest Funding Round$107M (USD), Series C
Jan 2023
- InvestorsCITIC
& 5 more
- Employee Count70
Funding Insights of HighTide Therapeutics
HighTide Therapeutics has successfully raised a total of $107M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $107 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $107M
- Total Rounds 2
- Last Round Series C — $107M
- Investors Count 6
All 2 funding rounds of HighTide Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2023 | $107M | Series C | – | Tcmhealthcare | |
| Dec 2020 | – | Series B | – | CITIC Securities, Cowin Capital | – |
6 investors in total: 6 institutional.
Investors in HighTide Therapeutics
HighTide Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include CITIC, TCM Health Care and Yuexiu Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Yuexiu Capital is engaged in financial services and asset management. | – | yuexiufund.com | Guangzhou, China | |
- | – | cowincapital.com.cn | - | |
TCM Health Care is focused on Traditional Chinese Medicine therapies. | 2012 | tcmhealthcare.com.au | Leeming, Australia | |
- | – | hongdefund.com | - | |
Provider of investment, wealth & asset management services | 1995 | cs.ecitic.com | Beijing, China | |
- | – | blueocean.capital | - |
Investor details for HighTide Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of HighTide Therapeutics
7 people are tracked at HighTide Therapeutics (7 in leadership); the tracked headcount is 70.
| Name | Role | Group |
|---|---|---|
Alex Liberman | Director, Clinical Science | Leadership |
Liping Liu | Founder, CEO & CSO | Leadership |
Tianwei | Vice President, Discovery Research | Leadership |
Susan Gamble | Senior Director, Regulatory Affairs | Leadership |
Gwen Melincoff | Chief Business Advisor | Leadership |
Wan-Jen Yang | Director Of Biology | Leadership |
Cathryn Bennett | Vp, Clinical Operations | Leadership |
Complete people profiles for HighTide Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of HighTide Therapeutics
HighTide Therapeutics is a publicly listed company on the HKEX with ticker symbol 2511 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Dec 2023
- Listed onHKG: 2511
- Listed entityHightide Therapeutics Inc
- Exchange sectorHealth technology
- ISINKYG4568L1023
- Share price3.42 HKD (+1.93% on the day) · 2026-10-09
- Market capitalisation2,040,947,630.00 HKD
- EPS (diluted, trailing year)-0.60 HKD
- Volume (last session)2,917,500
Financials of HighTide Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -265.7M HKD | -235.7M HKD |
| 2024 | – | -413.9M HKD | -475.8M HKD |
| 2023 | – | -1.04B HKD | -454.4M HKD |
| 2022 | – | -221.2M HKD | -261.4M HKD |
| 2021 | – | -266.5M HKD | -157.3M HKD |
Detailed financial statements for HighTide Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of HighTide Therapeutics
4 dated milestones of HighTide Therapeutics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded HighTide Therapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $107.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of HighTide Therapeutics
HighTide Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Ironwood Pharma, Nimbus Therapeutics, Adocia and Altimmune, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| adocia.com | 2005 | Lyon, France | $26M | – | Therapeutics for diabetes and obesity treatment are developed. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. | |
| ardelyx.com | 2007 | Fremont, United States | $61.1M | 37 | Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | |
| mirumpharma.com | 2018 | Menlo Park, United States | $120M | 196 | Small molecule therapeutics are developed for rare diseases treatment. | |
| madrigalpharma.com | 2011 | Conshohocken, United States | $38.38M | 56 | Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis | |
| carmot.us | 2008 | Berkeley, United States | $385.52M | – | Disease-modifying therapies for metabolic diseases are developed. | |
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. |
Detailed competitors of HighTide Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of HighTide Therapeutics
The website of HighTide Therapeutics (hightidetx.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▲ 84.2% vs previous month
Latest news on Hightide Therapeutics
Complete news archive for HighTide Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to HighTide Therapeutics
10 companies that operate in the same segment as HighTide Therapeutics (Metabolic Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Developer of cortisol modulators for the treatment of various diseases | 1998 | Menlo Park, California, United States | – | USD 761.41 M | 500 | |
Developer of therapies for the treatment of endocrine-related diseases and cancers | 2008 | San Diego, California, United States | USD 103.5 M | USD 1.04 M | 437 | |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | 2009 | Cambridge, Massachusetts, United States | USD 685 M | – | 81 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Solutions for biomarker discovery and diagnostic testing are provided. | 2000 | Morrisville, United States | USD 165.87 M | – | – | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about HighTide Therapeutics
HighTide Therapeutics was founded in 2011 and raised its 1st funding round 9 years after it was founded.
HighTide Therapeutics is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
HighTide Therapeutics is a funded company, having raised a total of $107M across 2 funding rounds to date.
HighTide Therapeutics has 70 employees.
Developer of small molecule based therapeutics for the treatment of liver, gastrointestinal, and metabolic disorders. The companys lead product candidate HTD-1801 used for the treatment of primary sclerosing cholangitis, NAFLDNASH, and hypercholesterolemia. Other products of the company include HTD4010 used for the treatment of acute pancreatitis, HTD1804 for obesiry, HTD1805 for metabolic disease, and HTD2802 for IBD.
HighTide Therapeutics's top competitors include Ironwood Pharma, Nimbus Therapeutics and Adocia.
Yes, HighTide Therapeutics is publicly traded on HKEX under the ticker symbol 2511.
HighTide Therapeutics has 6 investors. Key investors include CITIC, TCM Health Care, Yuexiu Capital, Hongde Fund Management, and Cowin Capital.